Silexion Therapeutics — Third Quarter 2026 Earnings Summary
Financial Performance:
- Net loss for the three months ended September 30, 2026, was approximately $2.5 million, a 24.2% decrease from $3.3 million in the same period in 2025.
- Net loss for the nine months ended September 30, 2026, was approximately $8.8 million, a 17.3% increase from $7.5 million in the same period in 2025.
- Research and development (R&D) expenses for the three months ended September 30, 2026, were approximately $1.3 million, a 40.9% decrease from $2.2 million in the prior year period.
- R&D expenses for the nine months ended September 30, 2026, were approximately $4.9 million, a 28.9% increase from $3.8 million in the prior year period, driven by the operational ramp-up of the Phase 2/3 clinical trial.
- General and administrative (G&A) expenses for the three months ended September 30, 2026, were approximately $1.4 million, a 27.3% increase from $1.1 million in the prior year period.
- G&A expenses for the nine months ended September 30, 2026, were approximately $4.2 million, a 20.0% increase from $3.5 million in the prior year period.
- Cash and cash equivalents were $4.8 million as of September 30, 2026, down from $6.0 million as of December 31, 2025, and up from $2.2 million as of June 30, 2026.
- Total shareholders' equity was $3.0 million as of September 30, 2026, compared to $2.6 million as of December 31, 2025.
- Total liabilities were $3.9 million as of September 30, 2026, compared to $4.6 million as of December 31, 2025.
Guidance and Future Outlook:
- The Company plans to enroll the first group of patients in the Phase 2/3 trial and bring additional hospitals in Israel and Germany into the trial.
- Additional Israeli oncology centers and leading academic medical institutions in Germany are progressing through site activation and are expected to join the trial in the coming months.
- The Company intends to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies.
- The Company faces substantial doubt about its ability to continue as a going concern.
- The Company must maintain compliance with Nasdaq listing requirements, including shareholders' equity and minimum bid price requirements.
Business Segments and Product Lines:
- SIL204, a second-generation small interfering RNA (siRNA) product candidate, entered active patient treatment with the first patient dosed in a Phase 2/3 clinical trial for locally advanced pancreatic cancer (LAPC) on September 30, 2026.
- The Phase 2/3 trial is a prospective, randomized, controlled, multinational, open-label study evaluating SIL204 in combination with standard-of-care chemotherapy versus chemotherapy alone in treatment-naïve patients with unresectable Stage 3 LAPC harboring confirmed KRAS mutations.
- The study structure includes an initial safety run-in cohort of approximately 18 patients, followed by an expansion into a randomized cohort of approximately 166 patients.
- SIL204 is administered via a dual-route regimen combining direct EUS-guided intratumoral delivery to the primary tumor with subcutaneous injections for systemic exposure.
- New translational data indicates a coordinated immune-sensitization signature across four KRAS mutations (G12D, G12V, G12C, and G12R) and a native lipoprotein-mediated uptake mechanism supporting systemic administration.
- Preclinical findings showed upregulation of FAS (CD95) and downregulation of HLA-G in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines.
- Pharmacokinetic, cellular uptake kinetics, and biodistribution studies are ongoing.
Market and Competitive Landscape:
- Silexion Therapeutics is a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers, which are described as the most common oncogenic gene driver in human cancers.
- The Company's first-generation product candidate showed a positive trend compared to chemotherapy alone in a Phase 2a trial.
Risks and Challenges:
- Risks include the degree of success of ongoing and planned clinical trials, the risk that early observations may not predict later results, and the ability to enroll and treat patients on anticipated timelines.
- The Company faces risks related to the regulatory environment, compliance complexities, and the potential inability to secure additional capital.
- There is substantial doubt about the Company's ability to continue as a going concern.
- The Company must maintain Nasdaq listing compliance, including shareholders' equity and minimum bid price requirements.
Management Commentary and Tone:
- Chairman and CEO Ilan Hadar stated that the focus is on enrolling the first group of patients and expanding the trial to more hospitals in Israel and Germany.
- CFO Mirit Horenshtein Hadar noted that financial progress from recent financings strengthens the balance sheet and supports the advancement of SIL204.
- Management highlighted that laboratory work continues to strengthen the case for SIL204, suggesting it may help the immune system recognize cancer cells and uses natural blood carriers to enter cancer cells.
Other Key Points:
- During the third quarter, the Company completed a registered public offering with gross proceeds of approximately $2.5 million, a warrant inducement transaction with gross proceeds of approximately $0.84 million, and sales under its at-the-market facility for gross proceeds of approximately $1.9 million.
- On November 10, 2026, the Company effected a 1-for-24 reverse share split.
- A 1-for-10 reverse share split was previously effected on May 28, 2026.
- The Company has a Related Party Promissory Note of $0 as of September 30, 2026, compared to $1.6 million as of December 31, 2025.
- Trade payables increased to $1.2 million as of September 30, 2026, from $0.8 million as of December 31, 2025.
- Company
- SILEXION THERAPEUTICS CORP
- Sector
- Healthcare
- Industry
- Biotechnology